Sahar Safaee1, Masoumeh Fardi1,2, Nima Hemmat1, Neda Khosravi1, Afshin Derakhshani1,3, Nicola Silvestris3,4, Behzad Baradaran1. 1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 51656-65811, Iran. 2. Hematology Division, Immunology Department, Tabriz University of Medical Sciences, Tabriz 51656-65811, Iran. 3. IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy. 4. Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.
Abstract
BACKGROUND: Glioma is an aggressive type of brain tumor that originated from neuroglia cells, accounts for about 80% of all malignant brain tumors. Glioma aggressiveness has been associated with extreme cell proliferation, invasion of malignant cells, and resistance to chemotherapies. Due to resistance to common therapies, glioma affected patients' survival has not been remarkably improved. ZEB2 (SIP1) is a critical transcriptional regulator with various functions during embryonic development and wound healing that has abnormal expression in different malignancies, including brain tumors. ZEB2 overexpression in brain tumors is attributed to an unfavorable state of the malignancy. Therefore, we aimed to investigate some functions of ZEB2 in two different glioblastoma U87 and U373 cell lines. METHODS: In this study, we investigated the effect of ZEB2 knocking down on the apoptosis, cell cycle, cytotoxicity, scratch test of the two malignant brain tumor cell lines U87 and U373. Besides, we investigated possible proteins and microRNA, SMAD2, SMAD5, and miR-214, which interact with ZEB2 via in situ analysis. Then we evaluated candidate gene expression after ZEB2-specific knocking down. RESULTS: We found that ZEB2 suppression induced apoptosis in U87 and U373 cell lines. Besides, it had cytotoxic effects on both cell lines and reduced cell migration. Cell cycle analysis showed cell cycle arrest in G0/G1 and apoptosis induction in U87 and U373 cell lines receptively. Also, we have found that SAMAD2/5 expression was reduced after ZEB2-siRNA transfection and miR-214 upregulated after transfection. CONCLUSIONS: In line with previous investigations, our results indicated a critical oncogenic role for ZEB2 overexpression in brain glioma tumors. These properties make ZEB2 an essential molecule for further studies in the treatment of glioma cancer.
BACKGROUND:Glioma is an aggressive type of brain tumor that originated from neuroglia cells, accounts for about 80% of all malignant brain tumors. Glioma aggressiveness has been associated with extreme cell proliferation, invasion of malignant cells, and resistance to chemotherapies. Due to resistance to common therapies, glioma affected patients' survival has not been remarkably improved. ZEB2 (SIP1) is a critical transcriptional regulator with various functions during embryonic development and wound healing that has abnormal expression in different malignancies, including brain tumors. ZEB2 overexpression in brain tumors is attributed to an unfavorable state of the malignancy. Therefore, we aimed to investigate some functions of ZEB2 in two different glioblastomaU87 and U373 cell lines. METHODS: In this study, we investigated the effect of ZEB2 knocking down on the apoptosis, cell cycle, cytotoxicity, scratch test of the two malignant brain tumor cell lines U87 and U373. Besides, we investigated possible proteins and microRNA, SMAD2, SMAD5, and miR-214, which interact with ZEB2 via in situ analysis. Then we evaluated candidate gene expression after ZEB2-specific knocking down. RESULTS: We found that ZEB2 suppression induced apoptosis in U87 and U373 cell lines. Besides, it had cytotoxic effects on both cell lines and reduced cell migration. Cell cycle analysis showed cell cycle arrest in G0/G1 and apoptosis induction in U87 and U373 cell lines receptively. Also, we have found that SAMAD2/5 expression was reduced after ZEB2-siRNA transfection and miR-214 upregulated after transfection. CONCLUSIONS: In line with previous investigations, our results indicated a critical oncogenic role for ZEB2 overexpression in brain glioma tumors. These properties make ZEB2 an essential molecule for further studies in the treatment of glioma cancer.
Authors: K Verschueren; J E Remacle; C Collart; H Kraft; B S Baker; P Tylzanowski; L Nelles; G Wuytens; M T Su; R Bodmer; J C Smith; D Huylebroeck Journal: J Biol Chem Date: 1999-07-16 Impact factor: 5.157
Authors: A Emre Sayan; Thomas R Griffiths; Raj Pal; Gareth J Browne; Andrew Ruddick; Tamer Yagci; Richard Edwards; Nick J Mayer; Hasan Qazi; Sandeep Goyal; Serena Fernandez; Kees Straatman; George D D Jones; Karen J Bowman; Alexandra Colquhoun; J Kilian Mellon; Marina Kriajevska; Eugene Tulchinsky Journal: Proc Natl Acad Sci U S A Date: 2009-08-17 Impact factor: 11.205
Authors: Maricarmen Hernández-Rodríguez; Pablo I Mendoza Sánchez; Joel Martínez; Martha E Macías Pérez; Erika Rosales Cruz; Teresa Żołek; Dorota Maciejewska; René Miranda Ruvalcaba; Elvia Mera Jiménez; María I Nicolás-Vázquez Journal: Molecules Date: 2022-02-26 Impact factor: 4.411